SAM
AMPH icon

Sawgrass Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Sawgrass Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-63,600
Closed -$1.3M – 169
2019
Q1 		$1.3M Buy
63,600
+51,890
+443% +$1.16M 0.06% 107
2018
Q4 		$233K Buy
+11,710
New +$231K 0.01% 191

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sawgrass Asset Management's AMPH Position: Q2 2019 in Review

Sawgrass Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2019, closing a stake of 63,600 shares — an estimated $1.3M sold.

Sawgrass Asset Management first reported a position in AMPH in Q4 2018 and held it in 2 quarters. The position peaked at $1.3M in Q1 2019. 133 funds tracked by Wall St. Rank hold AMPH as of Q2 2019.

  • Sawgrass Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Sawgrass Asset Management sold 63,600 Amphastar Pharmaceuticals shares in Q2 2019, an estimated $1.3M.
  • Sawgrass Asset Management first reported a position in Amphastar Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Sawgrass Asset Management's Amphastar Pharmaceuticals position peaked at $1.3M in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2019.

Based on Sawgrass Asset Management's 13F filing for Q2 2019, filed 23 Jul 2019.